STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Bactiguard (STO:BACTIB) started the year by increasing sales of its own product portfolio and delivered approx. 87,600 units, which is more than half of the total volume in 2015. License revenues were lower due to the adjusted order from C.R Bard, but as of March the order situation is back at a stable level. Operating profit was negative, but mayor payments of accounts receivable contributed to a positive cash flow.
Bactiguard (STO:BACTIB) started the year by increasing sales of its own product portfolio and delivered approx. 87,600 units, which is more than half of the total volume in 2015. License revenues were lower due to the adjusted order from C.R Bard, but as of March the order situation is back at a stable level. Operating profit was negative, but mayor payments of accounts receivable contributed to a positive cash flow.
